Back to Search
Start Over
Frequent fragility of randomized controlled trials for HCC treatment
- Source :
- BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021), BMC Cancer
- Publication Year :
- 2021
- Publisher :
- BMC, 2021.
-
Abstract
- Background The fragility index (FI) of trial results can provide a measure of confidence in the positive effects reported in randomized controlled trials (RCTs). The aim of this study was to calculate the FI of RCTs supporting HCC treatments. Methods A methodological systematic review of RCTs in HCC treatments was conducted. Two-arm studies with randomized and positive results for a time-to-event outcome were eligible for the FI calculation. Results A total of 6 trails were included in this analysis. The median FI was 0.5 (IQR 0–10). FI was ≤7 in 4 (66.7%) of 6 trials; in those trials the fragility quotient was ≤1%. Conclusion Many phase 3 RCTs supporting HCC treatments have a low FI, which challenges the confidence in concluding the superiority of these drugs over control treatments.
- Subjects :
- Cancer Research
medicine.medical_specialty
Carcinoma, Hepatocellular
030204 cardiovascular system & hematology
lcsh:RC254-282
law.invention
03 medical and health sciences
0302 clinical medicine
Fragility
Randomized controlled trial
law
Internal medicine
Outcome Assessment, Health Care
Genetics
medicine
Humans
030212 general & internal medicine
Randomized Controlled Trials as Topic
Models, Statistical
business.industry
Liver Neoplasms
Endpoint
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Oncology
Clinical Trials, Phase III as Topic
Randomized controlled trials
business
Research Article
Fragility index
Subjects
Details
- Language :
- English
- ISSN :
- 14712407
- Volume :
- 21
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- BMC Cancer
- Accession number :
- edsair.doi.dedup.....817d5b08ac45689f3da81aa26ddc594e